UniSuper Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

UniSuper Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.11M	Buy	3,687 +1,187	+47%	+$358K	0.01%	496
2026 Q1	$827K	Hold	2,500	–	–	0.01%	553
2025 Q4	$994K	Buy	2,500 +300	+14%	+$133K	0.01%	545
2025 Q3	$1M	Hold	2,200	–	–	0.01%	564
2025 Q2	$717K	Sell	2,200 -300	-12%	-$83K	﹤0.01%	583
2025 Q1	$675K	Hold	2,500	–	–	0.01%	583
2024 Q4	$588K	Sell	2,500 -500	-17%	-$131K	﹤0.01%	583
2024 Q3	$825K	Hold	3,000	–	–	0.01%	587
2024 Q2	$729K	Buy	3,000 +1,200	+67%	+$189K	0.01%	666
2024 Q1	$269K	Buy	1,800 +900	+100%	+$150K	﹤0.01%	899
2023 Q4	$172K	Hold	900	–	–	﹤0.01%	552
2023 Q3	$159K	Hold	900	–	–	﹤0.01%	507
2023 Q2	$171K	Buy	+900	New	+$178K	﹤0.01%	501

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UniSuper Management's ALNY Position: Q2 2026 in Review

UniSuper Management increased its Alnylam Pharmaceuticals (ALNY) stake by 47% in Q2 2026, buying an estimated $358K and bringing the position to 3,687 shares worth $1.11M. The position accounts for 0.01% of the portfolio, ranked #496.

UniSuper Management first reported a position in ALNY in Q2 2023 and has held it in 13 quarters since. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

UniSuper Management held 3,687 shares of Alnylam Pharmaceuticals worth $1.11M as of Q2 2026.
UniSuper Management bought 1,187 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $358K.
Alnylam Pharmaceuticals made up 0.01% of UniSuper Management's portfolio in Q2 2026, its #496 holding.
UniSuper Management first reported a position in Alnylam Pharmaceuticals in Q2 2023 and has held it in 13 quarters since.
790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on UniSuper Management's 13F filing for Q2 2026, filed 14 Aug 2026.